Search results: (10000)
News Do real-world clinical practice data confirm the results of cenobamate treatment in the clinical program?
A recent study by Spanish authors presents the largest dataset of patients with published cenobamate treatment results under prolonged observation in real-world clinical practice at the time of article publication. Data are derived from an expanded access program for a population with highly drug-resistant focal seizures.
News Safety of aPCC in Real Practice – Results of the BAHAS Project
What are the experiences with activated prothrombin complex concentrate (aPCC) in controlling bleeding or preventing its recurrence in acquired hemophilia A? The BAHAS project from Spanish real practice offers answers.
News Thromboprophylaxis in Generalized Pancreatic Cancer
Pancreatic adenocarcinoma is one of the tumors with the highest risk of developing thromboembolic disease (TED). Although anticoagulant treatment reduces the risk of TED, its positive effect on the overall survival of patients has not yet been proven.
News Does Emicizumab Change Routine Clinical Practice?
With the increasing number of patients with hemophilia A being treated with emicizumab, the question arises whether its use in any way changes established clinical practice. A team of American authors sought answers based on a survey conducted among the treating physicians of these patients. The findings were presented at the 13th Annual EAHAD Congress, which took place at the beginning of February in The Hague, Netherlands.
News What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?
Fresh findings from the BE ACTIVE study were published this year in the journal Rheumatology, which evaluated the effects of long-term treatment of individuals with psoriatic arthritis (PsA) with bimekizumab in terms of patient-reported outcomes (PROs).
News Analysis of the Benefits and Risks of Superabsorbent Dressings in the Treatment of Moderate to Highly Exuding Leg Ulcers
A study on the benefits and risks of superabsorbent dressings compared to standard dressings in the treatment of moderate to highly exuding leg ulcers was published last year in The International Journal of Lower Extremity Wounds.
News Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
The aging population of individuals with hemophilia brings new experiences and challenges, leading to the search for the safest and most effective treatments and prevention strategies for diseases typical of older age, particularly cardiovascular and cerebrovascular diseases. It is important to recognize that these complications pose a real risk for individuals with hemophilia, a risk that has thus far been somewhat underestimated.
News Venetostart – The First Comprehensive Mobile Application with Practical Information for Venetoclax Treatment
Abbvie has developed the comprehensive mobile application Venetostart with practical information needed in clinical practice for administering venetoclax (Venclyxto), which is indicated for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
News ID 360 – Immunodeficiency in Interdisciplinary Collaboration 2022
For the second time, a two-day meeting titled "ID 360 – Immunodeficiency in Interdisciplinary Collaboration" took place, this time on March 25–26, 2022, in Prague. Several current topics were discussed during this professional event, which brings together experts who care for patients with primary or secondary immunodeficiencies. The meeting was professionally guaranteed by Prof. MUDr. Anna Šedivá, DSc., from the Institute of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital Motol in Prague.
News Impact of Initial RAAS Inhibitor on Hospitalization Risk in HFrEF Patients
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is considered a key step in the treatment of heart failure with reduced ejection fraction (HFrEF). The preferred medication currently is the angiotensin II receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan, which has shown to improve the prognosis of patients with HFrEF. A recently published study compared the initiation of ARNI or angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) in patients with HFrEF who were not previously treated with a RAAS inhibitor in real-world practice.
News ERS 2023: Erdostein and its Metabolite Met-1 Modulate Innate Immunity and Oxidative Stress in SARS-CoV-2 Infection
As part of the September congress of the European Respiratory Society (ERS 2023), the issue of COVID-19 was also addressed. Among the late-breaking messages was an e-poster by experts from the University of Milan, who in their study examined the potential of erdosteine and its active metabolite Met-1 in treating this disease, based on research into its application to cells infected with SARS-CoV-2.
News ITP with Severe Hemorrhagic Manifestations Associated with COVID-19 – Case Study
There can be numerous causes of newly acquired immune thrombocytopenia (ITP), often being idiopathic. Severe COVID-19 can be associated with ITP manifestations where the standard first-line treatment may not be effective. In life-threatening bleeding situations, adding romiplostim has proven effective, as illustrated by the following case study from authors in Montreal, Canada.
News Focused on the Effect of Teriflunomide on Lymphocyte Subpopulations
Teriflunomide is a common choice for long-term therapy of the relapsing-remitting form of multiple sclerosis. The use of this immunomodulatory agent results in a decrease in lymphocyte numbers. Its effect on different lymphocyte subpopulations, however, has not been fully elucidated. Italian authors of a study published in the journal Neurology: Neuroimmunology and Neuroinflammation attempted to refine this knowledge.
News Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism
The relationship between the level of antithyroid antibodies and the required dose of levothyroxine in substitution for autoimmune hypothyroidism is a poorly explored question. Therefore, a retrospective study of more than 300 patients was conducted, and we bring you a brief summary.
News Does the Risk of Recurrence of Differentiated Thyroid Carcinoma Differ by Gender?
Differentiated thyroid carcinomas (DTC) are typically diagnosed at more advanced stages in men than in women, and mortality from this disease is higher among men than women. However, it was not entirely clear whether the risk of DTC recurrence is influenced by the patient's gender independently of the disease stage at the time of diagnosis. The aim of the Canadian authors' study was to assess whether male gender is an independent risk factor for DTC recurrence.
News Turoctocog Alfa Pegol in Surgical Procedures – Experiences from Pathfinder 3 and 5 Studies
The Haemophilia journal published data in May 2020 from 2 studies that summarize experiences with turoctocog alfa pegol during surgical procedures in adults, adolescents, and children with hemophilia A.
News Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy – Results of the Final Analysis of Clinical Studies
Previously published results of clinical studies have shown that in patients refractory to crizotinib therapy, the administration of brigatinib led to a high rate of therapeutic response (systemic and intracranial) and simultaneously improved median progression-free survival. Additional results presented at this year's ASCO congress included the final outcomes of studies focusing on the administration of brigatinib specifically in patients refractory to crizotinib therapy.
News Assessment of the Effectiveness of Superabsorbent Dressings from the Perspective of Doctors and Patients
The Journal of Wound Care published the results of an observational study on the benefits of Resposorb Super superabsorbent dressings in the treatment of acute and chronic wounds with higher levels of exudate.
News Two Current Perspectives on the Importance of (Par)enteral Nutrition in Cancer Patients
Adequate (par)enteral nutrition is crucial for cancer patients in terms of prognosis and quality of life. The following recent studies examined parenteral nutrition as an alternative to ileostomy in patients with colorectal anastomosis and muscle mass loss in patients with metastatic cancer.
News Evaluation of Continuity of Care in Patients with mCRC – Baseline Characteristics of Participants in the PROMETCO Study
During this year's World Congress of the European Society for Medical Oncology (ESMO) on gastrointestinal malignancies, the baseline characteristics of participants in the ongoing PROMETCO study, which focuses on evaluating the continuity of care in patients with metastatic colorectal cancer (mCRC), were presented.
News Improving Physical Function in Patients with COPD in Routine Clinical Practice
The increase in exercise capacity with the use of a fixed-dose combination of tiotropium and olodaterol in the Respimat inhaler has already been demonstrated in clinical studies in patients with chronic obstructive pulmonary disease (COPD). Italian authors evaluated its benefits in real-world practice and also focused on patient satisfaction with the inhaler.
News Regular Walking as an Intervention to Support the Quality of Life of Diabetics
Diabetes mellitus (DM), as a chronic and in many cases disabling disease, limits patients in various aspects of their lives. Therefore, it is important to consider the quality of life of diabetics as part of treatment and to seek ways to appropriately support it and enable patients to be as actively involved in everyday life as possible. The American journal Diabetes Care published the results of a study evaluating the impact of regular walking on the quality of life in DM.
News When to Initiate Dabigatran Therapy in Patients with Atrial Fibrillation After First Ischemic Stroke?
After a cardioembolic ischemic stroke (iCMP), approximately 5% of patients experience a recurrence within the first 14 days without anticoagulant therapy. The aim of the retrospective observational study presented below was to evaluate the optimal timing of initiating dabigatran anticoagulant therapy with respect to the risk of intracerebral hemorrhage.